Meta-Analysis of the Effect of Intensive Therapy on Nephropathy in Type I Diabetes Mellitus

  • Ping H. Wang
  • Joseph Lau
  • Thomas C. Chalmers


The large-scale Diabetes Control and Complication Trial (DCCT) has convincingly demonstrated the benefits of intensive therapy on diabetic nephropathy, neuropathy, and retinopathy [1]. A meta-analysis of several smaller studies also reached the same conclusions on nephropathy and retinopathy [2]. Decades of debate over whether normalization of hyperglycaemia may retard or delay microvascular complications came to an end [3, 4]. As more randomized-controlled trials in diabetic patients are being conducted, meta-analysis will be a useful tool to study interventions in the prevention of diabetic complications. In this chapter, we review the principle, strengths, and limitations of meta-analysis and the results of meta-analysis of intensive glycaemic control on diabetic nephropathy. The clinical implications of intensive therapy, based on the results of DCCT and meta-analysis, are also discussed.


Diabetic Nephropathy Glycaemic Control Microvascular Complication Urinary Albumin Excretion Intensive Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986.CrossRefGoogle Scholar
  2. 2.
    Wang PH, Lau J, Chalmers CT. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993; 341: 1306–1309.PubMedCrossRefGoogle Scholar
  3. 3.
    Wang PH. Tight blood glucose control and diabetic complications. Lancet 1993; 342: 617–618.Google Scholar
  4. 4.
    Lasker RD. The diabetes control and complications trial-implications for policy and practice. N Engl J Med 1993; 329: 1053–1054.CrossRefGoogle Scholar
  5. 5.
    Sacks HS, Berner J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analyses of randomized controlled trials. N Engl J Med 1987; 316: 450–455.PubMedCrossRefGoogle Scholar
  6. 6.
    L’Abbe KA, Detsky AS, O’Rourke. Meta-analysis in clinical research. Ann Intern Med 1987; 107: 224–233.PubMedCrossRefGoogle Scholar
  7. 7.
    Liberati A, Himel HN, Chalmers TC. A quality assessment of randomized control trials of primary treatment of breast cancer. J Clin Oncol 1986; 4: 962–951.Google Scholar
  8. 8.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986; 7: 177–188.PubMedCrossRefGoogle Scholar
  9. 9.
    Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992; 327: 248–254.PubMedCrossRefGoogle Scholar
  10. 10.
    Antman EM, Lau J, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts: treatment for myocardial infarction. JAMA 1992; 268: 240–248.PubMedCrossRefGoogle Scholar
  11. 11.
    Rosenthal R. The »file drawer problem« and tolerance for null results. Psychol Bull 1979; 86: 638–641.CrossRefGoogle Scholar
  12. 12.
    The Kroc Collaborative Study Group. Blood glucose control and the evolution of diabetic retinopathy and albuminuria. N Engl J Med 1984; 311: 365–372.CrossRefGoogle Scholar
  13. 13.
    Deckert T, Lauritzen T, Parving HH, Christiansen JS, Steno Study Group. Effect of two years of strict metabolic functions in long term insulin-dependent diabetics. Diabetic Nephropathy 1984; 3: 6–10.Google Scholar
  14. 14.
    Wiseman MJ, Saunders AJ, Keen H, Viberti G. Effect of blood glucose control on increased glomerular filtration rate and kidney size in insulin-dependent diabetes. N Engl J Med 1985; 312: 617–621.PubMedCrossRefGoogle Scholar
  15. 15.
    Beck-Nielsen H, Richelsen B, Mogensen CE, et al. Effect of insulin pump treatment for one year on renal function and retinal morphology in patients with IDDM. Diabetes Care 1985; 312: 617–621.Google Scholar
  16. 16.
    Feldt-Rasmussen B, Mathiesen ER, Deckert T. Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet 1986; 2: 1300–1304.PubMedCrossRefGoogle Scholar
  17. 17.
    Christensen CK, Christiansen JS, Schmitz A, et al. Effect of continuous subcutaneous insulin infusion on kidney function and size in IDDM patients: a 2 year controlled study. J Diabetic Complications 1987; 1: 91–95.CrossRefGoogle Scholar
  18. 18.
    Dahl-Jørgensen K, Hanssen KF, Kierulf P, Bjøro T, Sandvik L, Aagenæs Ø. Reduction of urinary albumin excretion after 4 years of continuous subcutaneous insulin infusion in insulin-dependent diabetes mellitus. Acta Endocrinol (Copenh) 1988; 117: 19–25.Google Scholar
  19. 19.
    Reichard P, Berglund B, Britz A, Cars I, Nilsson BY, Rosenqvist U. Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. J Intern Med 1991; 230: 101–108.PubMedCrossRefGoogle Scholar
  20. 20.
    Holman RR, Dornan TL, Mayon-White V, et al. Prevention of deterioration of renal and sensory nerve function by more intensive management of insulin-dependent diabetic patients. Lancet 1983; 1: 204–207.PubMedCrossRefGoogle Scholar
  21. 21.
    Lestradet H, Papoz L, Hellouis De Menibus C, et al. Long-term study of mortality and vascular complications in juvenile-onset (type I) diabetes. Diabetes 1981; 30: 175–179.PubMedCrossRefGoogle Scholar
  22. 22.
    Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984; 311: 89–93.PubMedCrossRefGoogle Scholar
  23. 23.
    Wang PH, Lau J, Chalmers TC. Meta-analysis of the effects of intensive glycemic control on late complications of type I diabetes mellitus. Online J Curr Clin Trials 1993 May 21; Doc No 60.Google Scholar
  24. 24.
    Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102: 527–532.PubMedCrossRefGoogle Scholar
  25. 25.
    Unger RH, Foster DW. Diabetes mellitus. In: Wilson JD, Foster DW (eds). Williams Textbook of Endocrinology. Philadelphia: W.B. Saunders; 1992; pp 1255–1333.Google Scholar
  26. 26.
    Karam JH, Salber PR, Forsham PH. Pancreatic hormones and diabetes mellitus. In: Greenspan FS (ed). Basic and Clinical Endocrinology. East Norwalk: Appleton & Lange; 1991; pp 592–650.Google Scholar
  27. 27.
    Boden G, Reichard GA Jr, Hoeldtke RD, et al. Severe insulin-induced hypoglycaemia associated with deficiencies in the release of counterregulatory hormones. N Engl J Med 1981; 305: 1200–1205.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Ping H. Wang
  • Joseph Lau
  • Thomas C. Chalmers

There are no affiliations available

Personalised recommendations